Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Relmada Therapeutics, Inc.

RLMD Nasdaq Pharmaceutical Preparations Financials FY2015โ€“FY2025

Last close ยท Oct 23, 2026

$3.27

0.6%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$57.4M
Free cash flow Cash from operations minus capital spending.
โ€”
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$367M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.90 EPS (TTM)

What Relmada Therapeutics, Inc. does

No business description yet.

Legal name
RELMADA THERAPEUTICS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 19, 2026
Accession ยท CIK
0001213900-26-031862
0001553643

Revenue and margins

Relmada Therapeutics, Inc. had โ€” of revenue in fiscal 2025.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โ€” in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Relmada Therapeutics, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 30.9%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Relmada Therapeutics, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $212M$148M$96.3M$44.9M$93.0M
Current ratio 14.8x12.3x8.0x4.4x14.6x
Quick ratio 14.8x12.3x8.0x4.4x14.6x
Total assets $223M$153M$97.6M$45.8M$94.0M
Total liabilities $15.1M$12.5M$12.2M$10.3M$7.5M
Shareholders' equity $208M$140M$85.4M$35.5M$86.5M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY15FY16FY17FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ• โ€” โœ• โœ• โœ• โœ“ โœ• โœ“
Cash from operations exceeds net income โœ• โœ• โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ• โœ• โ€” โœ• โœ“ โœ• โœ• โœ• โœ“
Share count didn't rise โ€” โœ• โœ“ โ€” โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โœ• โœ• โ€” โœ“ โœ• โœ“ โœ“ โ€” โ€”
F-score โ€” / 30 / 72 / 7โ€” / 32 / 72 / 72 / 73 / 7โ€” / 6โ€” / 6
Accruals ratio 99.3%2.7%โˆ’100.6%โˆ’5.8%โˆ’26.9%โˆ’19.8%โˆ’28.3%โˆ’37.6%โˆ’39.4%โˆ’16.6%
Altman Z'' โˆ’29.50โˆ’111.56โˆ’123.6585.726.2412.400.91โˆ’12.80โˆ’49.20โˆ’10.21

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY15FY16FY17FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.0M โˆ’$0.0M โˆ’$1.3M โˆ’$0.8M $1.4M $1.2M $2.7M $5.2M โ€” โ€”
Net interest income $0.0M โˆ’$0.0M โˆ’$1.3M โˆ’$0.8M $1.4M $1.2M $2.7M $5.2M โ€” โ€”
Research and development $6.2M $1.3M $2.9M $7.0M $36.0M $90.6M $113M $54.8M $46.2M $26.9M
Operating income โˆ’$16.2M โˆ’$7.2M โˆ’$6.9M โˆ’$12.7M โˆ’$60.8M โˆ’$126M โˆ’$161M โˆ’$104M โˆ’$83.9M โˆ’$59.1M
Net income โˆ’$3.0M โˆ’$6.3M โˆ’$9.0M โˆ’$17.3M โˆ’$59.5M โˆ’$126M โˆ’$157M โˆ’$98.8M โˆ’$80.0M โˆ’$57.4M
Diluted EPS โˆ’$0.26 โˆ’$0.52 โˆ’$2.86 โˆ’$2.74 โˆ’$3.81 โˆ’$7.16 โˆ’$5.30 โˆ’$3.28 โˆ’$2.65 โˆ’$1.45
Diluted shares 0.01B 0.01B 0.00B 0.01B 0.02B 0.02B 0.03B 0.03B 0.03B 0.04B
Cash flow
Cash from operations โˆ’$13.1M โˆ’$6.5M โˆ’$6.0M โˆ’$10.5M โˆ’$27.8M โˆ’$91.9M โˆ’$104M โˆ’$51.7M โˆ’$51.8M โˆ’$45.8M
Capital expenditure $0.6M $0.0M $0.0M โ€” $182M โ€” โ€” โ€” โ€” โ€”
Free cash flow โˆ’$13.7M โˆ’$6.5M โˆ’$6.0M โ€” โˆ’$210M โ€” โ€” โ€” โ€” โ€”
Depreciation and amortization $0.1M $0.1M $0.0M $0.0M $0.0M $0.0M โ€” โ€” โ€” โ€”
Stock-based compensation $1.0M $0.7M $0.5M $1.2M $20.8M $40.5M $44.2M $43.8M $30.2M $13.9M
Balance sheet
Cash and short-term investments $8.5M $1.7M $2.2M $116M $117M $212M $148M $96.3M $44.9M $93.0M
Deposits โ€” โ€” โ€” $36.3M โ€” โ€” โ€” โ€” โ€” โ€”
Current assets $9.3M $2.5M $2.7M $117M $118M $223M $153M $97.5M $45.8M $94.0M
Current liabilities $3.1M $1.4M $5.9M $1.5M $12.6M $15.1M $12.5M $12.2M $10.3M $6.4M
Property and equipment, net $0.5M $0.0M $0.0M $0.0M $0.0M โ€” โ€” โ€” โ€” โ€”
Total assets $10.2M $2.8M $3.0M $117M $118M $223M $153M $97.6M $45.8M $94.0M
Total liabilities $3.2M $1.4M $8.6M $1.5M $12.6M $15.1M $12.5M $12.2M $10.3M $7.5M
Shareholders' equity $7.0M $1.5M โˆ’$5.5M $116M $106M $208M $140M $85.4M $35.5M $86.5M
Margins
Operating margin โˆ’953,858.8% 1,203,133.3% 517.5% 1,672.5% โˆ’4,348.1% โˆ’10,483.2% โˆ’6,063.4% โˆ’2,013.0% โ€” โ€”
EBITDA margin โˆ’950,635.3% 1,188,916.7% 517.3% 1,671.9% โˆ’4,347.8% โˆ’10,483.0% โ€” โ€” โ€” โ€”
Net margin โˆ’174,982.4% 1,047,750.0% 670.3% 2,275.7% โˆ’4,249.3% โˆ’10,487.2% โˆ’5,905.2% โˆ’1,917.7% โ€” โ€”
FCF margin โˆ’806,235.3% 1,086,000.0% 449.9% โ€” โˆ’14,998.6% โ€” โ€” โ€” โ€” โ€”
Net interest share of revenue 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% โ€” โ€”
Returns
Return on capital employed โˆ’225.7% โˆ’494.3% 242.2% โˆ’11.0% โˆ’57.6% โˆ’60.4% โˆ’114.8% โˆ’121.5% โˆ’236.1% โˆ’67.5%
Return on equity โˆ’42.2% โˆ’147.9% โ€” โˆ’15.0% โˆ’53.7% โˆ’80.1% โˆ’90.1% โˆ’87.5% โˆ’132.3% โˆ’94.0%
Return on assets โˆ’29.0% โˆ’96.1% โˆ’304.5% โˆ’14.8% โˆ’50.5% โˆ’73.6% โˆ’83.5% โˆ’78.9% โˆ’111.6% โˆ’82.1%
Return on tangible equity โˆ’42.2% โˆ’430.5% โ€” โˆ’15.0% โˆ’56.3% โˆ’60.4% โˆ’111.8% โˆ’115.7% โˆ’225.2% โˆ’66.3%
Growth
Revenue growth โ€” โˆ’135.3% โ€” โ€” โ€” โˆ’14.3% 121.8% 93.7% โ€” โ€”
Share count change โ€” 4.1% โˆ’74.0% โ€” 147.1% 12.6% 68.8% 1.6% 0.2% 30.9%
Financial health
Current ratio 3.0x 1.8x 0.5x 80.2x 9.4x 14.8x 12.3x 8.0x 4.4x 14.6x
Quick ratio 3.0x 1.8x 0.5x 80.2x 9.4x 14.8x 12.3x 8.0x 4.4x 14.6x
Capital allocation
Capex / revenue 33,076.5% โˆ’8,283.3% โˆ’0.9% โ€” 13,011.1% โ€” โ€” โ€” โ€” โ€”
Stock comp / revenue 58,976.5% โˆ’117,416.7% โˆ’38.7% โˆ’159.5% 1,484.9% 3,377.1% 1,661.8% 850.4% โ€” โ€”
Quality scores
Piotroski F-score โ€” 0.0 2.0 โ€” 2.0 2.0 2.0 3.0 โ€” โ€”
Altman Z'' โˆ’29.5 โˆ’111.6 โˆ’123.6 85.7 6.2 12.4 0.9 โˆ’12.8 โˆ’49.2 โˆ’10.2
Accruals ratio 99.3% 2.7% โˆ’100.6% โˆ’5.8% โˆ’26.9% โˆ’19.8% โˆ’28.3% โˆ’37.6% โˆ’39.4% โˆ’16.6%

Source: SEC EDGAR XBRL filings (CIK 0001553643). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open